Hi Joolly, I would happily buy more at the raise price & above,...

Hi Joolly,

I would happily buy more at the raise price & above, it’s certainly not about keeping that average, more about distribution of funds across a few biotechs I’m on, buying unloved stocks with good FA is not a bad thing, if you can handle waiting for fruition.

Some exciting things happening in Biotechland at the moment, including for us here on PIQ.

I haven’t had much time for research lately, but some new results out on Invokana CREDENCE & more on efficacy with eGFR & CKD:

https://www.prnewswire.com/news-releases/new-analysis-from-landmark-credence-study-shows-the-efficacy-and-safety-profiles-of-invokana-canagliflozin-are-consistent-across-various-levels-of-kidney-function-300955149.html

Janssen are also doing a CVD study using wearable technology with Apple for Invokana & heart disease. Not a lot to do with us here, but they really are pushing this drug along, including with their deal with Vifor USA (Cardio/renal disease specialists) to assist marketing Invokana; recently announced in International Pharma media.

I believe PIQ were also looking at Diabetes data if PromarkerD has the potential to predict diabetes related CVD, but I guess we will hear if this is the case post data analysis. DKD/CKD is good enough 4 years predictively pre clinical signs/damage evident in current laboratory results available.

Also, I was looking for some information on CPT code application process, this article I found helpful.

Laboratory tests come under category 1, but potentially also category 3 being a new technology. Obviously I’m no expert on these things, but try to understand these processes as best as possible & not get your head stuck in a pile of gobbledegook. Here is the article for you all to read if interested. If it’s been posted prior I apologise, not much reading time lately, but we need that code to move forward in the USA:

https://www.acro.org/washington/CPT_Approval_Process.pdf

With CE approval in Europe & Invokana under fast track approval process there too for CKD/CV indication, that takes approximately 6 months & was announced in August 2019.

http://www.pharmatimes.com/news/ema_accepts_license_extension_submission_for_invokana_and_vokanamet_1298972

So really it’s anyone’s guess where PromarkerD will kick off first, Europe appears to be well set now, with Atturos collaboration in Ireland also, TGA approval for Proteomics online portal hub for International use in diagnostics, plus with recent discussions in Japan & excellent IP protection in Asia with many countries covered including China (DKD/CKD is very prevalent in the Asian population as it is in Hispanic populations also) & from memory Sth Korea tops dialysis per capita globally.

A lot of focus on the USA happenings, USA Health Insurance Cos very interested in PromarkerD from prior announcements & some very large retrospective studies done on DKD/CKD Insurance databases recently (not by us), that is very telling on prevention to ESKD & the extremely costly part of kidney disease with dialysis & transplantation that has the USA Govt in crisis mode to prevent this huge amount of healthcare spending on a reasonably small population of healthcare recipients (see prior articles posted).

We must remember the PromarkerD footprint in other parts of the globe too, not just the USA in our investment here.

GLTAH